Sharewise Webinar With CEO Dr Daniel Tillett
Sharewise Webinar With CEO Dr Daniel Tillett
In this webinar hosted by Sharewise, Race Oncology CEO Dr Daniel Tillet presents the company’s current journey in the drug development process. Dr. Tillett covers bisantrene’s potential for global cancer patients, its unique ability...
Demystifying Clinical Trials & Approval Processes
Demystifying Clinical Trials & Approval Processes
In Hot Copper’s recent webinar “Demystifying clinical trials and approval processes for ASX-listed companies”, CEO Dr Daniel Tillett spoke with Sonia Madigan to discuss Race Oncology’s journey through the drug development process. Dr Tillett...
WTF With Race Oncology: Changing The Chemo Game – Stockhead
WTF With Race Oncology: Changing The Chemo Game – Stockhead
Race Oncology (ASX:RAC) CEO Dr Daniel Tillett joins Sarah Hughan at the Stockhead’s What The Facts?! video interview series to discuss side effects of traditional chemotherapy and the importance of protecting heart health as patients go through...
Race Oncology Looks To Accelerate Clinical Development Of Bisantrene
Race Oncology Looks To Accelerate Clinical Development Of Bisantrene
Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Daniel Tillett joins Jonathan Jackson in the Proactive studio to provide an update on the company’s movements over the last few months. Just recently, Race received a $4 million R&D tax...
Race Oncology (ASX: RAC) 2023 Annual General Meeting
Race Oncology (ASX: RAC) 2023 Annual General Meeting
The Race Oncology Annual General Meeting was held on Monday 27 November 2023. During the meeting the Race Board and management team provided an update on the forward-looking strategy, detailed new clinical development plans...
Race Oncology To Present “Highly Positive” AML Clinical Trial Outcomes At American Society Of Hematology Annual Conference
Race Oncology To Present “Highly Positive” AML Clinical Trial Outcomes At American Society Of Hematology Annual Conference
Race Oncology Ltd (ASX:RAC) has fielded “impressive” Phase 2 clinical trial results from its Acute Myeloid Leukaemia (AML) clinical trial. The interim clinical results are from an ongoing investigator-initiated Phase 2 trial of bisantrene in...
Race Oncology Kicks Off Safety Studies For RC220
Race Oncology Kicks Off Safety Studies For RC220
Race Oncology Ltd (ASX:RAC) executive director Dr Pete Smith speaks with Proactive soon after announcing the company has initiated the toxicology and safety pharmacology studies required to support human clinical trials of its flagship bisantrene formulation for...
March 2023 Update
March 2023 Update
Race Oncology Limited (“Race”) announces Executive Director and Chief Scientific Officer (CSO), Dr Daniel Tillett has advised his decision to step down from his roles. Dr Tillett will provide ongoing support through June 2023...
December 2022 Update
December 2022 Update
Race is pleased to announce the appointment of global pharmaceutical and commercial leader, Mr Damian Clarke-Bruce, as Managing Director and Chief Executive Officer, effective 1 February 2023. Mr Phil Lynch will return to his...
Race Oncology 2022 AGM Presentation
Race Oncology 2022 AGM Presentation
Race Oncology 2022 AGM Presentation by CEO Phil Lynch and CSO Dr Daniel Tillett....
